Why the study?
The real-world effectiveness of the EV-A71 vaccine against severe neurological complications such as encephalitis and its influence on circulating enterovirus serotypes required further clarification.
Does EV-A71 vaccination reduce encephalitis in children hospitalized with enterovirus-associated hand, foot, and mouth disease or herpangina?
Does EV-A71 vaccination reduce encephalitis in children hospitalized with enterovirus-associated hand, foot, and mouth disease or herpangina?
EV-A71 vaccination is highly effective in preventing severe encephalitis in children with enterovirus-associated hand, foot, and mouth disease or herpangina.
No takes yet. Share an insight, caveat, or question.
Supports possible encephalitis protection from EV-A71 vaccine in hospitalized children; leaves open practice change pending higher-quality evidence.
Nie et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: